Zoetis Inc. (ZTS)
- Previous Close
164.92 - Open
165.80 - Bid --
- Ask --
- Day's Range
164.92 - 168.39 - 52 Week Range
144.80 - 201.92 - Volume
2,108,445 - Avg. Volume
3,773,783 - Market Cap (intraday)
76.717B - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
32.33 - EPS (TTM)
5.20 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield 1.73 (1.03%)
- Ex-Dividend Date Apr 18, 2024
- 1y Target Est
213.70
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
www.zoetis.com14,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ZTS
Performance Overview: ZTS
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZTS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZTS
Valuation Measures
Market Cap
76.72B
Enterprise Value
81.51B
Trailing P/E
32.39
Forward P/E
29.15
PEG Ratio (5yr expected)
2.89
Price/Sales (ttm)
8.87
Price/Book (mrq)
15.17
Enterprise Value/Revenue
9.33
Enterprise Value/EBITDA
21.93
Financial Highlights
Profitability and Income Statement
Profit Margin
27.38%
Return on Assets (ttm)
13.99%
Return on Equity (ttm)
50.05%
Revenue (ttm)
8.73B
Net Income Avi to Common (ttm)
2.39B
Diluted EPS (ttm)
5.20
Balance Sheet and Cash Flow
Total Cash (mrq)
1.98B
Total Debt/Equity (mrq)
134.60%
Levered Free Cash Flow (ttm)
1.49B
Research Analysis: ZTS
Company Insights: ZTS
ZTS does not have Company Insights